FluoGuide proceeds to seventh dose level (36 mg) with FG001 in the ongoing clinical phase I/II trial following continued improvement of tumor illumination with increasing doses
Copenhagen, Denmark, 14 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 was well tolerated, and light was detected in all patients in the sixth cohort (24 mg), administered in the morning before surgery. The data from the sixth dose (24 mg) showed a continued improvement and clear illumination of the tumors in all three patients. The dose escalation committee has therefore recommended to initiate the seventh dose level (36 mg) in the ongoing clinical phase I/II trial.FluoGuide is conducting a clinical phase I/II trial evaluating safety and